ConductScience.org, home

Paper146282

Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.

Riccardi C and 4 others. Transplantation, 1978. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo. Papers, record 146282. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/146282

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.
PubMed
Journal
Transplantation
PubMed
Year
1978
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
0.59
iCite
Revised in PubMed
2019-07-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Riccardi CC
2Fioretti MCM C
3Giampietri AA
4Puccetti PP
5Goldin AA

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antigens, NeoplasmMajor topic
DacarbazineMajor topic
Graft RejectionMajor topic
Leukemia, ExperimentalMajor topic
TriazenesMajor topic
Animals
DNA
Floxuridine
Methotrexate
Mice
Neoplasm Transplantation
Transplantation, Homologous

Source PubMed

Download CSV of topics

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
28404974Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Oncotarget2017https://conductscience.org/library/papers/28404974PubMed
6561067Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives.Cancer Immunol Immunother1984https://conductscience.org/library/papers/6561067PubMed
3297373Chemical xenogenization of experimental tumors.Cancer Metastasis Rev1987https://conductscience.org/library/papers/3297373PubMed
2791188Two antiemetic regimens do not impair chemical xenogenization induced in vivo by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2791188PubMed
2458749DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity.Br J Cancer1988https://conductscience.org/library/papers/2458749PubMed
658308Long-term depression of two primary immune responses induced by a single dose of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC).Experientia1978https://conductscience.org/library/papers/658308PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/146282

GET https://conductscience.org/api/papers/v1/146282/authors